Precision Medicine

In this episode of Unscripted, guest host Steve Kheloussi, Principal Consultant with Kheloussi Consulting, sits down with Dr. John Fox, Senior Medical Director for the Americas at Illumina, to untangle the complexities of clinical utility. Drawing on his experience as a pediatrician and former health plan medical director, Dr. Fox explains why defining clinical utility remains a challenge for the industry and explores its critical role in precision medicine. From ending the "diagnostic odyssey" in pediatric rare diseases to the life-saving impact of large-panel biomarker testing in oncology, they discuss how the true value of a test lies in its power to change patient management and improve net health outcomes.

At the start of each year, AMCP brings together its Board, Foundation Officers, Committee & Affiliate leaders, and corporate partners for the Winter Leadership Meeting. It’s where we align on priorities, strengthen relationships, and ensure the work ahead reflects AMCP’s mission and trends and topics in managed care pharmacy.

The AMCP Research Institute announced the launch of a new medication therapy management (MTM) health care improvement initiative designed to assess and manage modifiable risk factors for dementia in asymptomatic, middle-aged adults. The initiative is supported by a generous grant from Lilly and aims to address critical gaps in the identification and intervention of early dementia risk.

Researchers from University of Utah Report Findings in Managed Care and Specialty Pharmacy (Optimization of Oncology Biomarker Testing In Managed Care: Best Practices and Consensus Recommendations From an Amcp Market Insights Program): Drugs and Therapies – Managed Care and Specialty Pharmacy

In this episode of Unscripted, the AMCP podcast, we talk with Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, about the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer.

Personalized medicine has moved from concept to proven science—but implementation lags behind. In this episode of Unscripted, Daryl Pritchard, Senior Vice President of Science Policy at the Personalized Medicine Coalition, discusses how precision medicine is transforming care and where critical gaps remain. He shares findings from recent studies showing how many patients are still lost along the testing-to-treatment pathway, even in well-established areas like non-small cell lung cancer, and explains what’s needed to bridge those gaps. The conversation highlights the role of payers, providers, and policymakers in aligning science, practice, and policy to deliver truly individualized care.

In June, the Academy of Managed Care Pharmacy (AMCP) convened leading experts from across health care disciplines for a two-day Precision Medicine Partnership Forum. The forum aimed to advance equitable and timely access to precision medicine, particularly in oncology.

In June, the Academy of Managed Care Pharmacy (AMCP) convened leading experts from across health care disciplines for a two-day Precision Medicine Partnership Forum. The forum aimed to advance equitable and timely access to precision medicine, particularly in oncology.

AMCP held a Precision Medicine Partnership Forum to examine solutions to challenges of access, consistency, and quality in precision oncology.

Last week, AMCP convened a diverse group of stakeholders for its Precision Medicine Partnership Forum to examine solutions that improve access, consistency, and quality in precision oncology.

Explore the poster abstract on precision oncology in the 2024 JMCP supplement.

Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. The National Institutes of Health estimated that cancer care cost the US $208.9 billion in 2020, $23.8 billion of which was due to lung cancer.